Sectors
OLMA
Olema Pharmaceuticals, Inc.
10.45
1 x 10.50
1 x 10.63
bid
ask
-
1.49
12.52%
09:39 AM
timesize
| Ytd | -58.22% | |
| 1y | 128.56% |
9.74
day range
11.18
4.91
52 week range
36.26
| Open | 10.98 | Prev Close | 11.94 | Low | 9.74 | High | 11.18 | Mkt Cap | 912.34M |
| Vol | 444.71K | Avg Vol | 1.44M | EPS | -2.02 | P/E | -5.17 | Forward P/E | -4.86 |
| Beta | 2.03 | Short Ratio | 7.94 | Inst. Own | 118.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 11.32 | 200-d Avg | 17.52 | 1yr Est | 40.70 |
| Income Statement | |||
| Operating Expenses | 57.99M | ||
| Research and Development Expense | 49.23M | ||
| Selling, General and Administrative Expense | 8.75M | ||
| Operating Income | -57.99M | ||
| Net Income | -53.09M | ||
| Net Income Common Stock | -53.09M | ||
| Net Income Common Stock (USD) | -53.09M | ||
| Consolidated Income | -53.09M | ||
| Earnings per Basic Share | -0.52 | ||
| Earnings per Basic Share (USD) | -0.52 | ||
| Earnings per Diluted Share | -0.52 | ||
| Earning Before Interest & Taxes (EBIT) | -53.09M | ||
| Earning Before Interest & Taxes (USD) | -53.09M | ||
| Weighted Average Shares | 102.80M | ||
| Weighted Average Shares Diluted | 102.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 52.55M | ||
| Cash and Equivalents (USD) | 52.55M | ||
| Investments | 452.80M | ||
| Investments Current | 452.80M | ||
| Current Assets | 513.23M | ||
| Property, Plant & Equipment Net | 921.00K | ||
| Total Assets | 530.65M | ||
| Debt Current | 956.00K | ||
| Total Debt | 3.96M | ||
| Current Liabilities | 47.17M | ||
| Debt Non-Current | 3.00M | ||
| Total Liabilities | 50.17M | ||
| Accumulated Retained Earnings (Deficit) | -650.65M | ||
| Accumulated Other Comprehensive Income | -460.00K | ||
| Shareholders Equity | 480.48M | ||
| Shareholders Equity (USD) | 480.48M | ||
| Assets Non-Current | 17.42M | ||
| Total Debt (USD) | 3.96M | ||
| Liabilities Non-Current | 3.00M | ||
| Trade and Non-Trade Payables | 3.72M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 420.00K | ||
| Net Cash Flow from Financing | 45.70M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 4.25M | ||
| Issuance (Purchase) of Equity Shares | 50.35M | ||
| Net Cash Flow from Investing | 4.53M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 4.53M | ||
| Net Cash Flow from Operations | -45.99M | ||
| Share Based Compensation | 10.15M | ||